These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Dialysis facility ownership and epoetin dosing in hemodialysis patients: a medical economic perspective. Cohen JT; Neumann PJ Am J Kidney Dis; 2007 Sep; 50(3):362-5. PubMed ID: 17720514 [No Abstract] [Full Text] [Related]
46. Medicare payment options for recombinant erythropoietin therapy. Sisk JE; Gianfrancesco FD; Coster JM Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):93-7. PubMed ID: 1928087 [TBL] [Abstract][Full Text] [Related]
47. Home dialysis in the new USA bundled payment plan: implications and impact. Golper TA; Guest S; Glickman JD; Turk J; Pulliam JP Perit Dial Int; 2011; 31(1):12-6. PubMed ID: 21282384 [TBL] [Abstract][Full Text] [Related]
48. Infection control requirements for dialysis facilities and clarification regarding guidance on parenteral medication vials. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2008 Aug; 57(32):875-6. PubMed ID: 18701878 [TBL] [Abstract][Full Text] [Related]
49. Case-mix adjustment for an expanded renal prospective payment system. Hirth RA; Turenne MN; Wheeler JR; Pozniak AS; Tedeschi P; Chuang CC; Pan Q; Slish K; Messana JM J Am Soc Nephrol; 2007 Sep; 18(9):2565-74. PubMed ID: 17675667 [TBL] [Abstract][Full Text] [Related]
50. Clinic ownership steady, but payment reform will be a test of survival. Neumann ME Nephrol News Issues; 2009 Jul; 23(8):46-7. PubMed ID: 19662910 [No Abstract] [Full Text] [Related]
51. Dialysis facility ownership and epoetin dosing in hemodialysis patients: a dialysis provider's perspective. Lazarus JM; Hakim RM Am J Kidney Dis; 2007 Sep; 50(3):366-70. PubMed ID: 17720515 [No Abstract] [Full Text] [Related]
52. Health care costs of peritoneal dialysis technique failure and dialysis modality switching. Chui BK; Manns B; Pannu N; Dong J; Wiebe N; Jindal K; Klarenbach SW Am J Kidney Dis; 2013 Jan; 61(1):104-11. PubMed ID: 22901772 [TBL] [Abstract][Full Text] [Related]
53. Will payment and quality-driven reform improve outcomes? Neumann ME Nephrol News Issues; 2012 Oct; 26(11):12. PubMed ID: 23427715 [No Abstract] [Full Text] [Related]
56. L-carnitine use in dialysis patients: is national coverage for supplementation justified? What were CMS regulators thinking--or were they? Steinman TI; Nissenson AR; Glassock RJ; Dickmeyer J; Mattern WD; Parker TF; Hull AR Nephrol News Issues; 2003 Apr; 17(5):28-30, 32-4, 36 passim. PubMed ID: 12715624 [TBL] [Abstract][Full Text] [Related]
57. Commentary: health care payment reform and academic medicine: threat or opportunity? Shomaker TS Acad Med; 2010 May; 85(5):756-8. PubMed ID: 20124876 [TBL] [Abstract][Full Text] [Related]
58. Improving adequacy of hemodialysis in Northern California ESRD patients: a final project report. Provider Participants and Medical Review Board of the TransPacific Renal Network. Brown J; Josephson M Adv Ren Replace Ther; 2000 Oct; 7(4 Suppl 1):S85-94. PubMed ID: 11053593 [TBL] [Abstract][Full Text] [Related]
59. And then there were--? Neumann ME Nephrol News Issues; 2011 Sep; 25(10):11. PubMed ID: 21998975 [No Abstract] [Full Text] [Related]
60. Dialysis facility ownership and epoetin dosing in hemodialysis patients: an overview. Weiner DE; Levey AS Am J Kidney Dis; 2007 Sep; 50(3):349-53. PubMed ID: 17720511 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]